Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis

X
Trial Profile

A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zetomipzomib (Primary) ; Mycophenolate mofetil; Prednisolone
  • Indications Lupus nephritis; Systemic lupus erythematosus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MISSION
  • Sponsors Kezar Life Sciences
  • Most Recent Events

    • 13 Nov 2023 According to Kezar media release, an encore poster presentation of the results at the upcoming 25th Asia-Pacific League of Associations for Rheumatology (APLAR) Congress, which is taking place December 7 - 11, 2023, in Thailand.
    • 10 Aug 2023 According to Kezar media release, The post-hoc analysis of MISSION Phase 2 patients with nephrotic range proteinuria and the unmet need of European patients with LN were presented as oral presentations at the 60th European Renal Association (ERA) Congress, which took place June 15-18, 2023 in Milan, Italy.
    • 10 Aug 2023 According to Kezar media release, The complete MISSION Phase 2 results, MISSION Phase 2 uCD163 data, and the unmet need of European patients with LN were presented as poster presentations at the European Alliance of Associations for Rheumatology (EULAR) 2023 Congress, which took place May 31 - June 3, 2023 in Milan, Italy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top